

Neuroendocrine Carcinoma -Epidemiology Forecast to 2028

<https://marketpublishers.com/r/N3EC9AEFDD1EN.html>

Date: January 2019

Pages: 50

Price: US\$ 3,250.00 (Single User License)

ID: N3EC9AEFDD1EN

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Neuroendocrine Carcinoma - Epidemiology Forecast, 2028' report provides a comprehensive analysis of the Neuroendocrine Carcinoma epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

MARKETS COVERED

United States

EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

Study Period: 2016-2028

Neuroendocrine Carcinoma Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Neuroendocrine Carcinoma in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders' views are also taken into account to provide a deep understanding of the Neuroendocrine Carcinoma outlook. It also includes the explanation of changing trends of epidemiology

outlining the Neuroendocrine Carcinoma scenario.
Neuroendocrine Carcinoma Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Neuroendocrine Carcinoma thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

REPORT SCOPE

The report covers detailed overview of Neuroendocrine Carcinoma explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

The Neuroendocrine Carcinoma Report assesses the disease risk and burden and highlights the unmet needs

It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

10 Year Forecast

7MM Coverage

Total Cases in Neuroendocrine Carcinoma

Key assessments

Patient Segmentation in Neuroendocrine Carcinoma

Neuroendocrine Carcinoma Risk & Burden

Factors driving growth in a specific Neuroendocrine Carcinoma patient population

Contents

1. REPORT INTRODUCTION

2. NEUROENDOCRINE CARCINOMA EPIDEMIOLOGY OVERVIEW AT A GLANCE

2.1. Patient Share Distribution of Neuroendocrine Carcinoma in 2016

2.2. Patient Share Distribution of Neuroendocrine Carcinoma in 2028

3. DISEASE BACKGROUND AND OVERVIEW: NEUROENDOCRINE CARCINOMA

3.1. Introduction

3.2. Symptoms

3.3. Etiology

3.4. Risk Factors

3.5. Pathophysiology

3.6. Diagnosis

3.7. Treatment

4. EPIDEMIOLOGY AND PATIENT POPULATION

4.1. Key Findings

4.2. Total Prevalent/ Incident Patient Population of Neuroendocrine Carcinoma in 7MM

4.3. Total Prevalent/ Incident Patient Population of Neuroendocrine Carcinoma in 7MM
– By Countries

5. EPIDEMIOLOGY OF NEUROENDOCRINE CARCINOMA BY COUNTRIES

5.1. United States

5.1.1. Assumptions and Rationale

5.1.2. Prevalent/Incident Cases of the Neuroendocrine Carcinoma

5.1.3. Sub-Type Specific cases of the Neuroendocrine Carcinoma

5.1.4. Sex- Specific Cases of the Neuroendocrine Carcinoma

5.1.5. Diagnosed Cases of the Neuroendocrine Carcinoma

5.2. EU5

5.3. Assumptions and Rationale

5.4. Germany

5.4.1. Assumptions and Rationale

5.4.2. Prevalent/Incident Cases of the Neuroendocrine Carcinoma

- 5.4.3. Sub-Type Specific cases of the Neuroendocrine Carcinoma
- 5.4.4. Sex- Specific Cases of the Neuroendocrine Carcinoma
- 5.4.5. Diagnosed Cases of the Neuroendocrine Carcinoma
- 5.5. France
 - 5.5.1. Assumptions and Rationale
 - 5.5.2. Prevalent/Incident Cases of the Neuroendocrine Carcinoma
 - 5.5.3. Sub-Type Specific cases of the Neuroendocrine Carcinoma
 - 5.5.4. Sex- Specific Cases of the Neuroendocrine Carcinoma
 - 5.5.5. Diagnosed Cases of the Neuroendocrine Carcinoma
- 5.6. Italy
 - 5.6.1. Assumptions and Rationale
 - 5.6.2. Prevalent/Incident Cases of the Neuroendocrine Carcinoma
 - 5.6.3. Sub-Type Specific cases of the Neuroendocrine Carcinoma
 - 5.6.4. Sex- Specific Cases of the Neuroendocrine Carcinoma
 - 5.6.5. Diagnosed Cases of the Neuroendocrine Carcinoma
- 5.7. Spain
 - 5.7.1. Assumptions and Rationale
 - 5.7.2. Prevalent/Incident Cases of the Neuroendocrine Carcinoma
 - 5.7.3. Sub-Type Specific cases of the Neuroendocrine Carcinoma
 - 5.7.4. Sex- Specific Cases of the Neuroendocrine Carcinoma
 - 5.7.5. Diagnosed Cases of the Neuroendocrine Carcinoma
- 5.8. United Kingdom
 - 5.8.1. Assumptions and Rationale
 - 5.8.2. Prevalent/Incident Cases of the Neuroendocrine Carcinoma
 - 5.8.3. Sub-Type Specific cases of the Neuroendocrine Carcinoma
 - 5.8.4. Sex- Specific Cases of the Neuroendocrine Carcinoma
 - 5.8.5. Diagnosed Cases of the Neuroendocrine Carcinoma
- 5.9. Japan
 - 5.9.1. Assumptions and Rationale
 - 5.9.2. Prevalent/Incident Cases of the Neuroendocrine Carcinoma
 - 5.9.3. Sub-Type Specific cases of the Neuroendocrine Carcinoma
 - 5.9.4. Sex- Specific Cases of the Neuroendocrine Carcinoma
 - 5.9.5. Diagnosed Cases of the Neuroendocrine Carcinoma

6. UNMET NEEDS OF THE NEUROENDOCRINE CARCINOMA

7. APPENDIX

8. REPORT METHODOLOGY

8.1. Sources

9. DELVEINSIGHT CAPABILITIES

10. DISCLAIMER

11. ABOUT DELVEINSIGHT

Indication Specific

List Of Tables

LIST OF TABLES

Table 1: Total Prevalent/Incident Cases of the Neuroendocrine Carcinoma in 7MM

Table 2: Total Prevalent/Incident Cases of the Neuroendocrine Carcinoma in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Neuroendocrine Carcinoma in United States (2016-2028)

Table 5: Sex- Specific Cases of the Neuroendocrine Carcinoma in United States (2016-2028)

Table 6: Diagnosed Cases of the Neuroendocrine Carcinoma in United States (2016-2028)

Table 7: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Germany (2016-2028)

Table 8: Sub-Type Specific cases of the Neuroendocrine Carcinoma in Germany (2016-2028)

Table 9: Sex- Specific Cases of the Neuroendocrine Carcinoma in Germany (2016-2028)

Table 10: Diagnosed Cases of the Neuroendocrine Carcinoma in Germany (2016-2028)

Table 11: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in France (2016-2028)

Table 12: Sub-Type Specific cases of the Neuroendocrine Carcinoma in France (2016-2028)

Table 13: Sex- Specific Cases of the Neuroendocrine Carcinoma in France (2016-2028)

Table 14: Diagnosed Cases of the Neuroendocrine Carcinoma in France (2016-2028)

Table 15: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Italy (2016-2028)

Table 16: Sub-Type Specific cases of the Neuroendocrine Carcinoma in Italy (2016-2028)

Table 17: Sex- Specific Cases of the Neuroendocrine Carcinoma in Italy (2016-2028)

Table 18: Diagnosed Cases of the Neuroendocrine Carcinoma in Italy (2016-2028)

Table 19: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Spain (2016-2028)

Table 20: Sub-Type Specific cases of the Neuroendocrine Carcinoma in Spain (2016-2028)

Table 21: Sex- Specific Cases of the Neuroendocrine Carcinoma in Spain (2016-2028)

Table 22: Diagnosed Cases of the Neuroendocrine Carcinoma in Spain (2016-2028)

Table 23: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in UK
(2016-2028)

Table 24: Sub-Type Specific cases of the Neuroendocrine Carcinoma in UK
(2016-2028)

Table 25: Sex- Specific Cases of the Neuroendocrine Carcinoma in UK (2016-2028)

Table 26: Diagnosed Cases of the Neuroendocrine Carcinoma in UK (2016-2028)

Table 27: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Japan
(2016-2028)

Table 28: Sub-Type Specific cases of the Neuroendocrine Carcinoma in Japan
(2016-2028)

Table 29: Sex- Specific Cases of the Neuroendocrine Carcinoma in Japan (2016-2028)

Table 30: Diagnosed Cases of the Neuroendocrine Carcinoma in Japan (2016-2028)

List Of Figures

LIST OF FIGURES

Figure 1: Total Prevalent/Incident Cases of the Neuroendocrine Carcinoma in 7MM

Figure 2: Total Prevalent/Incident Cases of the Neuroendocrine Carcinoma in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Neuroendocrine Carcinoma in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Neuroendocrine Carcinoma in United States (2016-2028)

Figure 6: Diagnosed Cases of the Neuroendocrine Carcinoma in United States (2016-2028)

Figure 7: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Germany (2016-2028)

Figure 8: Sub-Type Specific cases of the Neuroendocrine Carcinoma in Germany (2016-2028)

Figure 9: Sex- Specific Cases of the Neuroendocrine Carcinoma in Germany (2016-2028)

Figure 10: Diagnosed Cases of the Neuroendocrine Carcinoma in Germany (2016-2028)

Figure 11: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in France (2016-2028)

Figure 12: Sub-Type Specific cases of the Neuroendocrine Carcinoma in France (2016-2028)

Figure 13: Sex- Specific Cases of the Neuroendocrine Carcinoma in France (2016-2028)

Figure 14: Diagnosed Cases of the Neuroendocrine Carcinoma in France (2016-2028)

Figure 15: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Italy (2016-2028)

Figure 16: Sub-Type Specific cases of the Neuroendocrine Carcinoma in Italy (2016-2028)

Figure 17: Sex- Specific Cases of the Neuroendocrine Carcinoma in Italy (2016-2028)

Figure 18: Diagnosed Cases of the Neuroendocrine Carcinoma in Italy (2016-2028)

Figure 19: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Spain (2016-2028)

Figure 20: Sub-Type Specific cases of the Neuroendocrine Carcinoma in Spain

(2016-2028)

Figure 21: Sex- Specific Cases of the Neuroendocrine Carcinoma in Spain (2016-2028)

Figure 22: Diagnosed Cases of the Neuroendocrine Carcinoma in Spain (2016-2028)

Figure 23: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in UK

(2016-2028)

Figure 24: Sub-Type Specific cases of the Neuroendocrine Carcinoma in UK

(2016-2028)

Figure 25: Sex- Specific Cases of the Neuroendocrine Carcinoma in UK (2016-2028)

Figure 26: Diagnosed Cases of the Neuroendocrine Carcinoma in UK (2016-2028)

Figure 27: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Japan

(2016-2028)

Figure 28: Sub-Type Specific cases of the Neuroendocrine Carcinoma in Japan

(2016-2028)

Figure 29: Sex- Specific Cases of the Neuroendocrine Carcinoma in Japan (2016-2028)

Figure 30: Diagnosed Cases of the Neuroendocrine Carcinoma in Japan (2016-2028)

I would like to order

Product name: Neuroendocrine Carcinoma -Epidemiology Forecast to 2028

Product link: <https://marketpublishers.com/r/N3EC9AEFDD1EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N3EC9AEFDD1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970